Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Adaptimmune Limited Company Profile

12:10 EDT 24th April 2014 | BioPortfolio

Adaptimmune Limited is focused on the use of T cell therapy to treat HIV and cancer. It aims to utilize the body’s own machinery – the T lymphocyte cell – to target and destroy cancerous or infected cells.  Established in July 2008, Adaptimmune was set up to develop Immunocore Ltd’s (formerly Avidex/MediGeneLtd’s) unique T cell receptor engineering technology for adoptive T cell therapy.
Specifically, Adaptimmune makes use of the body’s ability to recognize infected or cancerous cells by enhancing the power of the T cell receptor (TCR) on killer T cells.
Cancerous or virally infected cells will typically present small parts or peptides of larger viral proteins or abnormal cancer proteins on their surface, offering a "molecular fingerprint", called an epitope, for killer T-cells from the immune system to identify. In a healthy individual, this triggers an immune response, eliminating the affected cell. However, viruses such as HIV mutate rapidly, swiftly disguising their fingerprints to allow them to hide from killer T-cells while cancer proteins are usually derived from self-proteins against which natural TCRs do not respond. Adaptimmune’s technology uniquely enhances the natural TCR affinity to either viral or cancer protein epitopes on an individual patient’s cells overcoming these obstacles for therapeutic benefit.
Adaptimmune has undertaken significant preclinical development with a number of pipeline TCRs to demonstrate their potency and specificity in vitro.  The TCRs in the current ovarian study are specific to the cancer testis antigen targets NY-ESO-1 157-165 (HLA A2; SLLMWITQC) and was engineered using Adaptimmune’s proprietary TCR engineering platform. It is poised to gather clinical safety and efficacy data on these and other TCRs with regulatory approvals for human trials in HIV and multiple cancers now in place.

 

Location

57 Jubilee Avenue
Abingdon
Oxford
Oxfordshire
OX14 4RX
UK

Contact

Phone: +44 (0) 1235 438642
Fax: +44 (0) 1235 438607
Email: info@adaptimmune.com


News Articles [19 Associated News Articles listed on BioPortfolio]

Adaptimmune receives $3.5 million boost for breast cancer cell therapy

The U.K.'s Biomedical Catalyst Fund has awarded $3.5 million to Adaptimmune to expedite the development of the company's seco -More- 

Adaptimmune wins fund payout

Biotech firm Adaptimmune has been awarded £2.1 million from the UK government’s Biomedical Catalyst Fund, which was set up to push forward translational research. The £180 million fund, managed by...

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical R...

Adaptimmune Appoints Dr Jonathan Knowles as Chairman of the Board (News)

20 November, 2013: Oxford, U.K & Philadelphia, U.S — Adaptimmune, the T cell therapy company pioneering engineered T cell receptors for the treatment of cancer and infectious disease, ...

Adaptimmune Announces Award of £2.1m from the Biomedical Catalyst Fund (News)

25 March 2014: Oxford, UK and Philadelphia, USA - Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK's ...

Adaptimmune receives £2.1m grant from Biomedical Catalyst Fund

Adaptimmune has received £2.1m grant from the Biomedical Catalyst Fund to advance the development of company’s second engineered T cell therapy program into the clinic in triple negative breast can...

Adaptimmune Announces Full-time Appointment of James Noble as Chief Executive Officer (News)

26 March 2014: Oxford, UK & Philadelphia, USA - Adaptimmune Ltd, the biotechnology company focused on the use of engineered T cells to treat cancer, announces the full-time appointment of ...

Adaptimmune reports positive results for multiple myeloma T-cell trial

UK-headquartered biotechnology firm Adaptimmune has reported encouraging early stage results for its T-cell receptor (TCR) technology in multiple myeloma – highlighting promising response rates,...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Adaptimmune Limited

Adaptimmune Limited is focused on the use of T cell therapy to treat HIV and cancer. It aims to utilize the body’s own machinery – the T lymphocyte cell – to target and destroy can...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located...

More Information about "Adaptimmune Limited" on BioPortfolio

We have published hundreds of Adaptimmune Limited news stories on BioPortfolio along with dozens of Adaptimmune Limited Clinical Trials and PubMed Articles about Adaptimmune Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Adaptimmune Limited Companies in our database. You can also find out about relevant Adaptimmune Limited Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement